| Literature DB >> 35366293 |
Vladimir Shvartz1, Maria Sokolskaya1, Andrey Petrosyan1, Artak Ispiryan1, Sergey Donakanyan1, Leo Bockeria1, Olga Bockeria1.
Abstract
BACKGROUND: Understanding of the risk factors for the development of adverse outcomes after aortic valve replacement is necessary to develop timely preventive measures and to improve the results of surgical treatment.Entities:
Keywords: aortic stenosis; aortic valve replacement; predictors of adverse outcomes
Year: 2022 PMID: 35366293 PMCID: PMC8955830 DOI: 10.3390/pathophysiology29010010
Source DB: PubMed Journal: Pathophysiology ISSN: 0928-4680
Clinical parameters of patients.
| Parameters | All | Mortality | No Mortality |
|
|---|---|---|---|---|
| N | 742 | 22 | 720 | |
| Age, years | 63(57; 69) | 66 (62; 70) | 63 (56; 69) | 0.131 |
| Male gender, % | 58 | 45 | 58 | 0.225 |
| BMI, kg/m2 | 28(25; 32) | 31 (28; 34) | 28.4 (25; 32) | 0.025 |
| Weight, kg | 80 (70; 89) | 78 (72; 92) | 80 (70; 89) | 0.620 |
| BSA, m2 | 1.9 (1.85; 2.01) | 1.9 (1.83; 2.04) | 1.9 (1.86; 2.01) | 0.125 |
| Hypertension, | 93 | 93 | 93 | 0.987 |
| Smoking, | 12 | 0 | 12 | 0.427 |
| IHD, | 51 | 79 | 50 | 0.035 |
| Prior AMI, | 7 | 21 | 6 | 0.022 |
| Stroke, | 4 | 0 | 4 | 0.409 |
| Diabetes, | 14 | 38 | 13 | 0.006 |
| COPD, | 6 | 7 | 6 | 0.803 |
| CKD, | 11.7 | 22.7 | 11 | 0.104 |
| CHF NYHA class III-IV, % | 71.5 | 69 | 71.6 | 0.849 |
| ASD, | <1 | 7 | <1 | 0.004 |
| VSD, | <1 | 0 | <1 | 0.871 |
| MV disease, % | 10 | 32 | 9.5 | <0.001 |
| TV disease, % | 9.2 | 22.7 | 8.8 | 0.025 |
| Arrhythmia | 23 | 41 | 23 | 0.049 |
| AF, % | 13 | 18 | 12 | 0.419 |
| Atrial flutter, % | 2 | 0 | 2 | 0.588 |
| FVE, % | 2 | 14 | 2 | <0.001 |
| VT, % | <1 | 0 | <1 | 0.844 |
| Sick sinus syndrome, % | <1 | 0 | <1 | 0.746 |
| AV block, % | 3 | 14 | 3 | 0.014 |
| Sinus rhythm, % | 87 | 93 | 87 | 0.692 |
| Cerebrovascular disease, % | 28 | 50 | 28 | 0.074 |
| Peripheral vascular disease, % | 22 | 36 | 22 | 0.223 |
| Concomitant oncological disease, % | 9 | 7 | 9 | 0.799 |
BMI—body mass index; BSA—body surface area; IHD—ischemic heart disease; AMI—acute myocardial infarction; COPD—chronic obstructive pulmonary disease; CKD—chronic kidney disease; CHF NYHA—chronic heart failure New York Heart Association classification; ASD—atrial septal disease; VSD—ventricular septal disease; MV—mitral valve; TV—tricuspid valve; AF—atrial fibrillation; FVE—frequent ventricular ectopy; VT—ventricular tachycardia; AV block—atrioventricular block.
Instrumental and laboratory characteristics of patients and drug therapy before surgery.
| Parameters | All | Mortality | No Mortality |
|
|---|---|---|---|---|
| N | 742 | 22 | 720 | |
| Echocardiographic parameters | ||||
| LVEF, % | 64 (58; 67) | 63 (58; 67) | 64 (58; 67) | 0.974 |
| LVEDD/BSA, cm/m2 | 2.6 (2.3; 2.9) | 2.99 (2.72; 3.77) | 2.6 (2.3; 2.9) | 0.001 |
| LVESD/BSA, cm/m2 | 1.68(1.49; 1.93) | 1.98 (1.75; 2.12) | 1.67(1.49; 1.91) | 0.008 |
| LVEDV/BSA, mL/m2 | 61.5 (49; 78) | 67 (59; 116) | 61.4 (50; 78) | 0.103 |
| LVESV/BSA, mL/m2 | 22 (17; 30) | 26 (22; 31) | 22 (17; 30) | 0.152 |
| Peak gradient, mm Hg | 96 (80; 112) | 95 (86; 105) | 96 (80; 112) | 0.912 |
| Peak velocity, m/s | 3.5 (2.8; 4.2) | 3.7 (2.9; 4.2) | 3.5 (2.8; 4.2) | 0.451 |
| Mean gradient, mm Hg | 55 (44; 66) | 58 (45; 62) | 54 (44; 67) | 0.944 |
| Fibrous ring of the aortic valve, mm | 23 (22; 25) | 22 (21; 25) | 23 (22; 25) | 0.174 |
| Bicuspid aortic valve, % | 14.8 | 9 | 15 | 0.201 |
| Moderate AR, % | 21 | 36 | 21 | 0.401 |
| Severe AR, % | 5.9 | 9 | 5.8 | 0.733 |
| EOA, cm2 | 0.7 (0.55; 0.8) | 0.65 (0.6; 0.8) | 0.7 (0.55; 0.8) | 0.233 |
| LA volume, mL3 | 109 (90; 140) | 132 (102; 145) | 109 (90; 140) | 0.542 |
| Laboratory parameters | ||||
| Hemoglobin level, g/L | 136 (126; 146) | 118 (111; 134) | 137 (127; 146) | <0.001 |
| Hematocrit, % | 41 (38; 44) | 36.5 (35; 39) | 41 (38; 44) | <0.001 |
| WBC, 109/L | 7.2 (6; 8.6) | 7.1 (6.6; 8.8) | 7.2 (6; 8.6) | 0.539 |
| Neutrophils, 109/L | 4.6 (3.6; 5.6) | 4.8 (3.7; 5.5) | 4.6 (3.6; 5.6) | 0.549 |
| Neutrophils, % | 60 (53; 65) | 67 (58; 71) | 59 (53; 65) | 0.032 |
| glucose, mmoL/L | 5.3 (4.9; 5.9) | 5.7 (5; 7,4) | 5.3 (4.9; 5.9) | 0.059 |
| Fibrinogen, g/L | 4.1 (3.7; 4.7) | 4.7 (4.3; 4.9) | 4.05 (3.6; 4.6) | 0.064 |
| Creatinine, mkmoL/L | 82 (72; 96) | 87 (69; 108) | 82 (72; 96) | 0.481 |
| eGFR, mL/min | 87 (69; 103) | 75 (62; 100) | 87 (69; 103) | 0.129 |
| eGFR, mL/min per 1,73 m2 (MDRD) | 78(66; 90) | 71(51; 90) | 78(66; 89) | 0.154 |
| Drug therapy | ||||
| Beta-blockers, % | 49 | 64 | 49 | 0.403 |
| ACE inhibitors, % | 31 | 18 | 32 | 0.448 |
| ARA, % | 17 | 27 | 16 | 0.536 |
| Calcium antagonists, % | 12 | 27 | 11 | 0.363 |
| Statins, % | 32 | 36 | 32 | 0.802 |
| Nitrates, % | 8 | 9 | 8 | 0.964 |
| Thiazide diuretics, % | 9 | 0 | 10 | 0.576 |
| Loop diuretics, % | 12 | 27 | 11 | 0.369 |
| Potassium-sparing diuretics, % | 21 | 36 | 21 | 0.386 |
| Antiarrhythmic drugs, % | 5 | 9 | 5 | 0.813 |
LV EF—left ventricular ejection fraction; LVEDD—left ventricular end diastolic diameter; BSA—body surface area; LVEDV—left ventricular end diastolic volume; LVESD—left ventricular end systolic diameter; LVESV—left ventricular end systolic volume; AR—aortic regurgitation, EOA—effective orifice area; LA—left atrium; WBC—white blood cells; eGFR—estimated glomerular filtration rate; MDRD—modification of diet in renal disease; ACE—angiotensin-converting enzyme; ARA—angiotensin receptor antagonist.
Operational and postoperative parameters of patients.
| Parameters | All | Mortality | No Mortality |
|
|---|---|---|---|---|
| N | 742 | 22 | 720 | |
| CPB time, min | 137 (120; 163) | 185 (149; 215) | 137 (120; 161) | <0.001 |
| ACC time, min | 69 (61; 85) | 78 (65; 125) | 69 (61; 84) | 0.029 |
| AVR + CABG, % | 13.4 | 22.7 | 13 | 0.440 |
| AVR + MVR, % | 7 | 22.7 | 6.5 | <0.001 |
| AVR + MV plasty,% | 3.2 | 9 | 3 | 0.629 |
| AVR + MV repair (in total),% | 10 | 31.8 | 9.5 | <0.001 |
| AVR + TVR,% | <1 | 0 | <1 | 0.982 |
| AVR + TV plasty,% | 9 | 22.7 | 8.6 | <0.001 |
| AVR + TV repair (in total),% | 9.2 | 22.7 | 8.8 | 0.025 |
| AVR + CryoMaze procedure,% | 2.9 | 9 | 2.8 | 0.614 |
| 3 and more procedures,% | 8.3 | 27.3 | 7.8 | 0.001 |
| ICU time, days | 1 (1; 1) | 6 (2; 12) | 1 (1; 1) | <0.001 |
| Length of stay, days | 7 (6; 9) | 19 (12; 21) | 7 (6; 9) | 0.005 |
CPB—cardiopulmonary bypass; ACC—aortic cross-clamp; AVR—aortic valve replacement; CABG—coronary artery bypass grafting; MVR—mitral valve replacement; MV—mitral valve; TVR—tricuspid valve replacement; TV—tricuspid valve; ICU time – intensive care unit time.
The results of ROC analysis for the initial quantitative clinical, instrumental and laboratory parameters, associated with mortality.
| Parameters | Cut-Off Point | AUC (CI) | Se | Sp |
|
|---|---|---|---|---|---|
| Age, y | >62 | 0.594 (0.558–0.630) | 77.3 | 45.6 | 0.594 |
| BMI, kg/m2 | >30 | 0.640 (0.605–0.675) | 72.7 | 56.8 | 0.027 |
| LVESD/BSA, cm/m2 | >1.68 | 0.657(0.617–0.695) | 85.0 | 50.80 | 0.009 |
| LVEDD/BSA, cm/m2 | >2.39 | 0.647 (0.607–0.686) | 952 | 33.2 | 0.014 |
| ACC time, min | >93 | 0.676 (0.640–0.710) | 50.0 | 82.7 | 0.010 |
| CPB time, min | >144 | 0.809 (0.778–0.837) | 95.5 | 58.2 | <0.001 |
| Hemoglobin level, g/L | ≤120 | 0.762 (0.728–0.793) | 59.1 | 85.7 | <0.001 |
| Hematocrit, % | ≤39 | 0.755 (0.721–0.786) | 77.3 | 62.5 | <0.001 |
| Neutrophils, % | >68 | 0.657 (0.615–0.697) | 50.0 | 87.3 | 0.067 |
| Preop creatinine level, mkmoL/L | >98 | 0.544(0.506–0.582) | 36.4 | 77.7 | 0.536 |
| eGFR, mL/min | ≤64 | 0.595(0.557–0.632) | 40.9 | 83.9 | 0.163 |
| eGFR, mL/min per 1,73 m2 (MDRD) | ≤67 | 0.584(0.551–0.626) | 50 | 73.5 | 0.212 |
| Risk of in-hospital death, (%) | >1.4 | 0.722(0.687–0.754) | 76.2 | 57.8 | <0.001 |
AUC—area under curve; CI—confidence interval; Se—sensitivity; Sp—specificity; BMI—body mass index; BSA—body surface area; LVESD—left ventricular end systolic diameter; LVEDD—left ventricular end diastolic diameter; ACC—aortic cross-clamp; CPB—cardiopulmonary bypass; eGFR—estimated glomerular filtration rate.
The results of univariate logistic regression analysis of the initial and surgical parameters.
| Parameters | Univariate Logistic Regression Analysis |
|
|---|---|---|
| BMI > 30 kg/m2 | 2.84 (1.15–7.01) | 0.019 |
| LVESD/BSA cm/m2 > 1.68 | 4.81 (1.03–22.5) | 0.023 |
| LVEDD/BSA cm/m2 > 2.39 | 5.01 (1.07–23.4) | 0.003 |
| IHD | 3.65 (1.01–13.2) | 0.029 |
| Prior AMI | 4.16 (1.11–15.7) | 0.064 |
| Diabetes | 3.88 (1.38–10.9) | 0.018 |
| Arrhythmia | 2.33 (0.98–5.57) | 0.063 |
| FVE | 9.78 (1.91–50.2) | 0.026 |
| AV block | 5.83 (1.19–28.2) | 0.067 |
| MV repair | 4.47 (1.76–11.3) | 0.004 |
| TV repair | 3.06 (1.09–8.58) | 0.053 |
| 3 and more procedures | 4.44 (1.67–11.8) | 0.007 |
| ACC time, min > 93 | 4.28 (1.7–10.77) | 0.003 |
| CPB time, min > 144 | 25.1 (3.3–189.1) | <0.001 |
| Hemoglobin level ≤ 120 g/L | 8.67 (3.6–20.83) | <0.001 |
| Hematocrit ≤ 39% | 5.64 (2.1–15.49) | <0.001 |
OR – odds ratio; CI - confidence interval; BMI—body mass index; BSA—body surface area; LVESD—left ventricular end systolic diameter; LVEDD—left ventricular end diastolic diameter; IHD—ischemic heart disease; AMI—acute myocardial infarction; FVE—frequent ventricular ectopy; AV block—atrioventricular block; MV—mitral valve; TV—tricuspid valve; ACC—aortic cross-clamp; CPB—cardiopulmonary bypass.
Multivariate logistic regression analysis.
| Parameters | Coefficient | Standard Error |
|
|---|---|---|---|
| FVE | 2.358 | 0.953 | 0.013 |
| CPB time, min > 144 | 2.417 | 1.102 | 0.028 |
| BMI > 30 kg/m2 | 1.335 | 0.720 | 0.063 |
| IHD | 1.181 | 0.813 | 0.146 |
| Hemoglobin level ≤ 120 g/L | 1.107 | 0.811 | 0.172 |
| Hematocrit ≤ 39% | 0.765 | 0.820 | 0.351 |
| TV repair | 0.703 | 0.806 | 0.383 |
FVE—frequent ventricular ectopy; CPB—cardiopulmonary bypass; BMI—body mass index; IHD—ischemic heart disease; TV—tricuspid valve.